Veozah & Cancer Risk: What Menopausal Women with Hot Flashes Should Know | Felice Gersh, MD

Why It Matters

If Vioza’s cancer risk proves real, millions of menopausal women could face a trade‑off between symptom relief and long‑term health, demanding stricter surveillance and informed prescribing decisions.

Key Takeaways

• Vioza (fezolinitant) blocks neurokinin‑3 receptors to treat hot flashes.
• Emerging data suggest a possible increased risk of various cancers.
• NK3R blockade may lower kisspeptin, a peptide that suppresses metastasis.
• Compensatory NK1R activation could promote tumor growth and angiogenesis.
• Long‑term safety studies and post‑marketing surveillance are urgently needed.

Summary

Dr. Felice Gersh discusses Vioza (generic fezolinitant), a newly approved neurokinin‑3 receptor antagonist marketed for moderate‑to‑severe menopausal vasomotor symptoms. While clinical trials such as Skylight and Moonlight demonstrated efficacy, recent peer‑reviewed research raises alarms about a potential link between the drug and increased neoplasm incidence. The article she cites highlights mechanistic concerns: NK3R blockade may suppress kisspeptin, a peptide known to inhibit metastasis, and trigger compensatory activation of the NK1R pathway, which has been implicated in tumor proliferation, angiogenesis, and metastasis. Meta‑analyses and pooled data from post‑marketing registries have consistently shown a statistically significant rise in various cancers, including melanoma, reproductive‑organ, and lung cancers, despite initial regulatory dismissal. Gersh emphasizes that these findings are not definitive proof of causality but warrant vigilance. She notes parallel safety signals regarding liver toxicity and stresses that peptide‑based therapies often have off‑target effects because peptides act in multiple tissues beyond the hypothalamus. The discussion underscores the need for large‑scale, long‑term safety monitoring before widespread adoption. For clinicians and patients, the takeaway is clear: weigh the non‑hormonal benefits of Vioza against uncertain long‑term cancer risks, prioritize evidence‑based hormone replacement when appropriate, and adopt broader lifestyle (macro) strategies for menopausal health while awaiting robust post‑marketing data.

Original Description

Veozah, also known as fezolinetant, is a newer non-hormonal medication used to treat moderate to severe hot flashes and night sweats in perimenopause and menopause.

In this talk, I discuss a recent 2026 paper (https://pubmed.ncbi.nlm.nih.gov/42137787/) that raises questions about a possible increased risk of non-benign tumors with fezolinetant. This does not mean Veozah has been proven to cause cancer. But it does mean there are safety signals worth paying attention to, especially because this medication works by blocking the neurokinin 3 receptor, a pathway that may affect other systems in the body.

I explain what neurokinin B, kisspeptin, and NK3 receptors are, why blocking one receptor can have downstream effects, and why long-term post-marketing safety data matters so much for newer drugs. I also discuss where Veozah may still have a role, particularly for women who truly cannot use hormone therapy, while emphasizing the importance of informed, cautious prescribing.

My goal is not to scare anyone. It is to help women understand that every drug has a risk-benefit profile, and new medications need careful long-term follow-up.

Watch for my latest Instagram lives at

https://www.instagram.com/dr.felicegersh

I am a full-time practicing doctor. I see patients in my office in Irvine, CA and worldwide via telemedicine. If you need more healthcare assistance than I can provide in a video series, please contact my office:

https://integrativemgi.com/

#Veozah #Fezolinetant #MenopauseHealth #HotFlashes #NightSweats #HormoneTherapy #WomensHealth #MenopauseTreatment #DrFeliceGersh

----- Contents of this video ---------------------------

00:00 What is Veozah?

01:00 How Veozah works for hot flashes

02:30 A new paper on cancer risk signals

04:00 Neurokinin 3 receptors and kisspeptin

06:00 Why blocking one pathway can affect others

08:00 Kisspeptin, cancer, and metastasis concerns

10:00 Why this does not prove Veozah causes cancer

11:00 Peptides and unintended downstream effects

13:00 Risk, benefit, and post-marketing safety data

15:00 When Veozah may still have a role

16:00 The bigger lesson: don’t assume “peptide” means safe